Asia · Regional markets · Mint

Already jumped 55% in 2026, PL Capital sees more returns in Sai Lifesciences shares | Check target, upside

Published by Mint · India 1 h ago

PL Capital believes the company is well positioned to benefit from increasing pharmaceutical outsourcing, a deep commercial pipeline and capacity expansion

Read the full article on Mint Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.livemint.com)

Also worth reading

Tech in Asia

How Vietjet’s US$250 million global asset freeze complicates its 600-aircraft financing plans

Pulse (Maeil Business)

HD Hyundai plans U.S. shipbuilding production hub with Kiewit

China Daily Business

Already jumped 55% in 2026, PL Capital sees more returns in Sai Lifesciences shares | Check target, upside

Share

Also worth reading

HSBC launches its first stablecoin for payments in Hong Kong

BlueStone Jewellery stock plunges 13% as firm swings back to losses in Q2

Even China’s wealthy are cutting back, deepening slump for Hermes and Cartier

How Vietjet’s US$250 million global asset freeze complicates its 600-aircraft financing plans

HD Hyundai plans U.S. shipbuilding production hub with Kiewit

Enhanced corporate ties bring more Chinese expertise to fuel Dubai's growth